Concerning prognosis, the expression level of SLC7A11 was negatively correlated with the overall survival (OS, p < 0.001, Figure 10D), first progression survival (FPS, p < 0.01, Figure 10E), and post progression survival (PPS, p < 0.001, Figure 10F) of gastric cancer patients, suggesting that SLC7A11 could be a therapeutic target for gastric cancer. The gene discussed is SLC7A11; the disease is gastric cancer.